Measuring Blood Biomarkers with Greater Sensitivity - Cathepsin B Assay Developed

An ultrasensitive biomarker assay for cathepsin B measurement in blood has been developed as a research tool. Cathepsin B is a lysosomal cysteine protease that is important to a wide variety of functions throughout the body. It is involved in broad spectrum of diseases, injury states, and infections including cancer, dementia, brain trauma, as well as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accurate measurement of cathepsin B is often challenging to achieve within blood samples due to interference or “noise”. This newly developed assay for cathepsin B offers increased accuracy and little to no background, which may facilitate research and enhance diagnostic utility of cathepsin B as a blood biomarker.


These studies were originally published in American Chemical Society (ACS), Omega


“Single Molecule Assay for Ultrasensitive Detection of Cathepsin B in Human Blood”

by

Bharani Thangavelu* and Angela M. Boutté

https://pubs.acs.org/doi/10.1021/acsomega.1c00180


To learn how our expertise in brain biomarkers can augment your research needs, visit Aries Biotech at https://www.ariesbiotechnologies.org.

15 views0 comments

Recent Posts

See All

Aries Biotech is pleased to announce new hours of operation! Effective 01 October 2022, hours of operation will be Monday-Thursday, 8am to 6pm (PST) by appointment. This change will help to accommod

Biomarkers for Neurological Disease and Dementia Aries Biotech and Neurovations are merging their expertise in research and development to measure biomarkers of dementia. Additional information for N